about
The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma[Mild bleeding diathesis in a 62-year-old woman with hereditary thrombocytopenia].Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma.HTLV-1-associated adult T cell leukemia is highly susceptible to Navitoclax due to enhanced Bax expression.Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus.Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.Performance assessment and benchmarking of autologous peripheral blood stem cell collection with two different apheresis devices.Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial.Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma.The impact of high-dose chemotherapy, autologous stem cell transplant and conventional chemotherapy on quality of life of long-term survivors with follicular lymphoma.Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma.Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells.The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas.
P50
Q28391289-FBE29069-284B-4585-859F-4B2B807FEE88Q33407771-19BC80FC-049C-48A5-BC6F-0E7B7E7AF096Q33421147-723DE68F-DBB6-48BB-9FE2-0B6C46B64E76Q33425096-6E082EBB-C497-4071-B4A3-A912B6890E53Q36384588-0EE4595C-CE3B-49AB-A811-6032FB9D9AA3Q38670952-5653B5CC-6A4D-49D3-8ADC-D5749EBF1909Q39303533-AF04B56F-80A4-4DC4-8909-EA482B2AE209Q40451358-8B80C013-B425-436B-AB28-44EF9423D663Q45513822-FAE427EC-9A28-4C27-AD99-6583B591CD9BQ48606065-CE28926C-DF96-4833-B8B2-D99138598CA7Q50929024-B5760568-98C3-431F-B6F7-AA72A3BA0911Q51088673-D0C0081C-B693-4C88-87A6-E214D52B156FQ53088316-C5D01AD6-A8E2-4AD7-9264-6BE17DB04267
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Mathias Witzens-Harig
@ast
Mathias Witzens-Harig
@en
Mathias Witzens-Harig
@es
Mathias Witzens-Harig
@nl
Mathias Witzens-Harig
@sl
type
label
Mathias Witzens-Harig
@ast
Mathias Witzens-Harig
@en
Mathias Witzens-Harig
@es
Mathias Witzens-Harig
@nl
Mathias Witzens-Harig
@sl
prefLabel
Mathias Witzens-Harig
@ast
Mathias Witzens-Harig
@en
Mathias Witzens-Harig
@es
Mathias Witzens-Harig
@nl
Mathias Witzens-Harig
@sl
P214
P1053
N-1790-2017
P106
P1153
6602294016
P21
P214
P31
P3829
P496
0000-0002-2799-4661
P735
P7859
viaf-308214338